<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29962">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01722617</url>
  </required_header>
  <id_info>
    <org_study_id>2011-A01349-32</org_study_id>
    <nct_id>NCT01722617</nct_id>
  </id_info>
  <brief_title>A Study to Validate Questionnaires FLARE and OM-RA-FLARE Measuring Disease Flares in Patients With Rheumatoid Arthritis.</brief_title>
  <acronym>FLARE</acronym>
  <official_title>A Study to Validate Questionnaires FLARE and OM-RA-FLARE Measuring Disease Flares in Patients With Rheumatoid Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Régional et Universitaire de Brest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Fort-de-France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bichat Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Poitiers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis (RA) is a rheumatic inflammatory synovitis characterized by pain and
      joint swelling as well as thickening synovial (pannus) lesions that are responsible of
      osteocartilaginous and tendon damage. It evolves in spurts or long and variable intensity
      interspersed with remissions.

      The effectiveness of treatment is based on the proportion of patients who achieve a certain
      degree of improvement over the initial level of various parameters such as response criteria
      ACR 20, 50 or 70% or EULAR based on the evolution of DAS 28 or DAS 44. These response
      criteria are now well validated but do not fully take into account the improvement of the
      patient's condition. In contrast, there is no questionnaire to identify the proportion of
      patients whose RA worsened between the medical visits. Such a questionnaire is necessary to
      detect flares outbreaks in daily practice and in randomized clinical trials, follow-up
      studies or longitudinal studies after drugs marketing to detect a reversal of disease
      activity.

      Both STPR group and OMERACT group have each developed such a new self-administered
      questionnaire (FLARE and OM-RA-FLARE) to detect the flare- in RA patients.

      The objective of this study is to validate the questionnaires FLARE and OM-RA-FLARE among RA
      patients using the methodology advocated by the OMERACT in terms of validity (truth),
      discriminating power (discrimination) and feasibility
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be 6 months of follow up including 3 medical visits for each patients:

        -  M0 (medical visit for inclusion)

        -  follow up between M0 - M3

        -  M3 (medical visit at 3 months after inclusion)

        -  follow up between M3 - M6

        -  M6 (medical visit at 6 months after inclusion)

      At the inclusion visit (M0), after the verification of inclusion and non-inclusion criteria,
      the following information will be collected:

        -  Socio-demographical data : age, sex, level of education (primary, secondary, college,
           university), occupational category (INSEE in 6 categories)

        -  Items of the ACR 1987 and ACR/EULAR 2010;

        -  Length of the RA

        -  Erosive or not (presence Yes / no)

        -  IgM rheumatoid factor (presence Yes / No)

        -  Anti CCP antbodies (presence Yes / No)

      During follow-up visits (M3 and M6), the elements collected are:

        1. by the study technician (TEC)

             -  the inflammatory activity index, evaluated by patient (RAPID-3);

             -  the functional limitations index (HAQ);

             -  the PASS questionnaire;

             -  the OM-RA-FLARE questionnaire;

             -  the FLARE questionnaire.

        2. by the doctor :

             -  elements of DAS 28, this includes a blood test that will be done in the city or in
                the hospital ;

             -  the doctor's decision at the end of the consultation, in terms of :

                  -  DMRADs: continuing the treatment, decreasing or increasing the dose, changing
                     it due to its ineffectiveness, changing it due to patients' intolerance.

                  -  Symptomatic treatments: continuing corticosteroids, increase the dose of
                     corticosteroids, corticosteroid infiltration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>The validity of the questionnaire FLARE.</measure>
    <time_frame>6 mois</time_frame>
    <safety_issue>No</safety_issue>
    <description>The validity of the questionnaire shows the characteristics of the questionnaires (its ability to comprise the aspects for which it was designed). It will be studied by calculating the correlation coefficients between FLARE / OM-RA-FLARE on one hand, and various measures of disease activities (DAS 28, RAPID-3, RAID and AUC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The discriminating power of the instrument FLARE.</measure>
    <time_frame>6 mois.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The discriminating power, i.e.the degree of precision for each particular instrument, considered individually, will be assessed by its reproducibility, sensitivity to change and its impact on medical decision making.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The feasibility of the questionnaire FLARE</measure>
    <time_frame>6 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The feasibility will be measured by the percentage of non-calculable scores (missing data) and the number of items that are not filled for calculable scores.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>DAS 28</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this group will be asked to fill basic questionnaires, but without the FLARE questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAS 28 + FLARE questionnaires</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will be asked to fill basic questionnaires and FLARE questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAS 28+FLARE + information to doctor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will fill basic and FLARE questionnaires which then will be transmitted to physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Patients in groups 2 and 3 will be asked to fill in questionnaires FLARE.</description>
    <arm_group_label>DAS 28 + FLARE questionnaires</arm_group_label>
    <arm_group_label>DAS 28+FLARE + information to doctor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years;

          -  Having Rheumatoid Arthritis (RA) since more than 6 months, meeting the ACR 1987 and
             the ACR / EULAR 2010;

          -  Treatment of RA:

               -  Treatment of disease modifying anti-rheumatic drugs (DRMADs) or biological
                  treatment stable for more than 2 months;

               -  Symptomatic treatment (including corticosteroid) stable for more than 2 months;

          -  Receive the medical exam first;

          -  Agreed and signed the informed consent form;

          -  Ability to comply with the study protocol;

          -  Having the social insurance coverage

        Exclusion Criteria:

          -  Patients undergoing surgery during the study period;

          -  Patients without any affiliation to a social security coverage (or entitled
             beneficiary);

          -  Patients under guardianship or trusteeship.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis Guillemin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC-EC Inserm, CHU de Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Fautrel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Rhumatologie, Groupe Hospitalier Pitié - Salpêtrière, Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Morel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'immunorhumatologie, Hôpital Lapeyronie, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francis Guillemin, MD, PhD.</last_name>
    <phone>+33 3 83 85 21 65</phone>
    <email>francis.guillemin@chu-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irawati Lemonnier, MPH, PhD.</last_name>
    <phone>+33 3 83 85 93 00</phone>
    <email>i.lemonnier@chu-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Rhumatologie, CHU Hôpital Général</name>
      <address>
        <city>Dijon</city>
        <state>Bourgogne</state>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Francis MAILLEFERT, MD</last_name>
      <phone>+33 3 80 29 37 45</phone>
      <email>jean-francis.maillefer@hu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Corinne CHEVALIER</last_name>
      <phone>+33 0 80 29 30 31</phone>
      <phone_ext>16815</phone_ext>
      <email>corinne.chevalier@chu-dijon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Francis MAILLEFERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine PIROTH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie, CHU La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <state>Bretagne</state>
        <zip>29607</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain SARAUX, MD</last_name>
      <phone>+33 2 98 34 72 67</phone>
      <email>alain.saraux@univ-brest.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie BIHANNIC</last_name>
      <phone>+ 33 2 98 14 50 02</phone>
      <email>nathalie.bihannic@chu-brest.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Alain SARAUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Divi CORNEC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valérie-Marie DEVAUCHELLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine JOUSSE-JOULIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry MARHADOUR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie, CHRU Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <state>Bretagne</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marie BERTHELOT, MD</last_name>
      <phone>+33 2 40 08 48 22</phone>
      <email>jeanmarie.berthelot@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sophie GIBELLI</last_name>
      <phone>+33 2 40 08 48 32</phone>
      <email>karen.batard@chu-nantes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Marie BERTHELOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie, CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <state>Franche-Comté</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel WENDLING, MD</last_name>
      <phone>+33 3 81 66 82 41</phone>
      <email>dwendling@chu-besancon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Lucy ROCCHITELLI</last_name>
      <phone>+33 03 81 21 93 28</phone>
      <email>lrocchitelli@chu-besancon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel WENDLING, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie, CHU Fort de France</name>
      <address>
        <city>Fort de France</city>
        <state>La Martinique</state>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georges JEAN-BAPTISE, MD, PhD</last_name>
      <email>gcd.jeanbaptiste@orange.fr</email>
    </contact>
    <contact_backup>
      <last_name>Michel DE BANDT, MD, PhD</last_name>
      <phone>+33 05 96 55 23 51</phone>
      <email>micheldebandt@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michel DE BANDT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie, Hôpitaux de Rouen</name>
      <address>
        <city>Rouen</city>
        <state>Normandie</state>
        <zip>76233</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier VITTECOQ, MD</last_name>
      <phone>+33 02 32 88 90 19</phone>
      <email>Olivier.Vittecoq@chu-rouen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Aissa MEGEUHOUT</last_name>
      <phone>+33 2 32 88 93 24</phone>
      <email>aissa.megeuhout@chu-rouen.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier VITTECOQ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry LEQUERRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie, CHU - Hôpital Sud A. Michallon</name>
      <address>
        <city>Grenoble</city>
        <state>Rhône-Alpes</state>
        <zip>38130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe GAUDIN, MD</last_name>
      <phone>+ 33 4 76 76 51 36</phone>
      <email>pgaudin@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Réjane GRUEL</last_name>
      <phone>+33 4 76 76 72 23</phone>
      <email>rgruel@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe GAUDIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mélanie GILSON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie, CHU Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thao PHAM, MD, PhD</last_name>
      <phone>+33 04 91 38 34 34</phone>
      <email>thao-pham@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Thao PHAM, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Alix LANFRANCHI DEBRA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fédération de Rhumatologie, CHU Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques MOREL, MD, PhD</last_name>
      <phone>+33 4 67 33 87 10</phone>
      <email>j-morel@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Aurore GUILLARDEAU</last_name>
      <phone>+33 4 67 33 77 91</phone>
      <email>a-guillardeau@chu-montpellier.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jacques MOREL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie, APHP - CHU Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MEYER, MD, PhD</last_name>
      <phone>+33 1 40 25 75 00</phone>
      <email>olivier.meyer@bch.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Hagit ZYLBERMAN-YONA</last_name>
      <phone>+33 1 40 25 70 27</phone>
      <email>hagit.zylberman-yona@bch.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier MEYER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magali BALLARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles HAYEM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien OTTAVIANI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabienne ROUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie, APHP - GH Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno FAUTREL, MD, PhD</last_name>
      <phone>+33 01 42 17 76 20</phone>
      <email>bruno.fautrel@psl.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nicolas VAILLANT</last_name>
      <phone>+33 1 42 17 71 97</phone>
      <email>nicolas.vaillant@psl.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Bruno FAUTREL</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Béatrice BANNEVILLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie, CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth SOLAU - GERVAIS, MD, PhD</last_name>
      <phone>+33 05 49 44 44 65</phone>
      <email>e.solau@chu-poitiers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Katia GOUROU</last_name>
      <phone>+33 5 49 44 32 83</phone>
      <email>katia.gourou@chu-poitiers.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth SOLAU - GERVAIS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel BRAULT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise DEBIAIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie, Hôpital Larey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud CONSTANTIN, MD</last_name>
      <phone>+33 5 67 77 17 57</phone>
      <email>constant@cict.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marie-Hélène CERATO</last_name>
      <phone>+33 5 61 77 73 97</phone>
      <email>cerato.mh@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Arnaud CONSTANTIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <lastchanged_date>November 5, 2012</lastchanged_date>
  <firstreceived_date>October 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
